Establishment Labs Lifts Full-Year Outlook as Q2 Revenue Surges 32%
ESTA has more than doubled off its 52-week low of $33.35.
Summary
Establishment Labs reported Q2 2026 revenue of $67.5 million, up 31.7% year-over-year, and raised full-year guidance to $269–$271 million. Adjusted EBITDA turned positive at $3.7 million, and cash improved to $71.2 million.
Key Events · Earnings and Guidance · ESTA
-
Q2 Revenue Beats, Up 32%
Revenue reached $67.5 million, a 31.7% increase from Q2 2025, driven by U.S. sales of $24.7 million (up 26% sequentially) and minimally invasive platform revenue of $12.1 million.
-
Full-Year Guidance Raised
Management lifted 2026 revenue guidance to $269–$271 million from the prior $266.5–$268.5 million, implying continued strong growth in the second half.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA improved to $3.7 million from a loss of $8.5 million a year ago, reflecting operating leverage as revenue scales.
-
Cash Position Strengthens
Cash balance rose to $71.2 million as of June 30, 2026, up $3.1 million from Q1 2026 and $16.5 million from the year-ago period.
Analysis · ESTA · Industrial Applications And Services
A strong second quarter saw revenue climb 31.7% to $67.5 million, topping consensus estimates and underscoring the momentum behind the company's minimally invasive breast aesthetics platform. Reflecting that confidence, management raised full-year 2026 revenue guidance to $269–$271 million. Adjusted EBITDA swung to a $3.7 million profit from a year-ago loss, while the cash balance improved sequentially to $71.2 million. The results mark a clear inflection toward profitability and cash generation, reinforcing the growth narrative.
At the time of this filing, ESTA was trading at $90.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $33.35 to $97.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.